Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2010

Roche Claims Phase III Data Supports Use of Avastin in Ovarian Cancer

  • Roche says new Phase III trial data supports the continued development of Avastin for treating ovarian cancer. Data from the ICON7 study showed that chemotherapy-naïve patients who received Avastin plus chemotherapy, followed by Avastin alone, had a 27% improvement in progression-free survival (PFS)compared with women receiving only chemotherapy. The data was presented at the recent Congress of the European Society of Medical Oncology.

    The firm says the latest data supports that reported earlier this year from the pivotal Phase III trial GOG0218 in ovarian cancer patients. This study found that combining Avastin with chemotherapy and then continuing Avastin therapy resulted in a 54% increase in PFS compared with chemotherapy alone. Trial GPOG0218 evaluated a higher dose of Avastin and longer treatment duration than trial ICON7.

    Roche says overall survival data from both studies has yet to be finalized, but to date favors the Avastin-containing study arms.

Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »